Physiological and pharmacological roles of melatonin in the pathophysiological components of cellular injury after ischemic stroke
- PMID: 32962330
- PMCID: PMC7672349
- DOI: 10.3906/sag-2008-32
Physiological and pharmacological roles of melatonin in the pathophysiological components of cellular injury after ischemic stroke
Abstract
Apart from its metabolic or physiological functions, melatonin has a potent cytoprotective activity in the physiological and pathological conditions. It is synthetized by the pineal gland and released into the blood circulation but particularly cerebrospinal fluid in a circadian manner. It can also easily diffuse through cellular membranes due its small size and lipophilic structure. Its cytoprotective activity has been linked to its potent free radical scavenger activity with the desirable characteristics of a clinically- reliable antioxidant. Melatonin detoxifies oxygen and nitrogen-based free radicals and oxidizing agents, including the highly toxic hydroxyl-and peroxynitrite radicals, initiating cellular damage. However, the cytoprotective activity of melatonin is complex and cannot be solely limited to its free radical scavenger activity. It regulates cellular signaling pathways through receptor– dependent and independent mechanisms. Most of these downstream molecules, such as PI3K/AKT pathway components, also contribute to the cytoprotective effects of melatonin. In this term, melatonin is a promising molecule for the treatment of neurodegenerative disorders, such as ischemic stroke, which melatonin reduces ischemic brain injury in animal models of ischemic stroke. It regulates also circadian rhythm proteins after ischemic stroke, playing roles in cellular survival. In this context, present article summarizes the possible role of melatonin in the pathophysiological events after ischemic stroke.
Keywords: apoptosis; circadian rhythm proteins; free radicals; melatonin; signaling; Ischemic stroke.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Conflict of interest statement
The authors declare no conflict of interest related to this paper.
References
-
- Flynn RW MacWalter RS Doney AS The cost of cerebral ischaemia. Neuropharmacology . 2008;55:250–256. - PubMed
-
- Feigin VL Lawes CM Bennett DA Barker-Collo SL Parag V Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. The Lancet Neurology . 2009;8:355–369. - PubMed
-
- Rosamond W Flegal K Friday G Furie K Go A Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation . 2008;115:e69–e171. - PubMed
-
- Wolfe CD Giroud M Kolominsky-Rabas P Dundas R Lemesle M Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. Stroke . 2000;31:2074–2079. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical